Dyglomera and Lisinopril
Supplement–drug interaction evidence from the TruthStack database.
| Severity | MODERATE |
|---|---|
| Evidence Tier | Moderate |
| Interaction Type | PHARMACODYNAMIC RISK |
| Mechanism | PHARMACODYNAMIC |
| Last Reviewed | 2026-03-03 |
Source Verification
Attestation METHODOLOGY_ATTESTED
Corpus manifest 26b2d684...
Last reviewed 2026-03-03
Primary source 26350732
Live attestation Query API — returns signed DAA ID per request
Data license CC BY 4.0
Summary
Dyglomera reduced systolic blood pressure by 9.4% in metabolic syndrome patients over 16 weeks (Kuate 2013, n=297). Lisinopril is an ACE inhibitor that lowers blood pressure. Combining may produce additive hypotensive effects. Monitor blood pressure and discuss with prescriber.
API Reference
GET https://api.truthstack.co/v1/check?c1=Dyglomera&c2=Lisinopril
Open, unauthenticated. Returns JSON. Developer documentation
Sources
Primary: 26350732
Related Interactions
What this page is and is not. TruthStack is an informational reference database that describes published pharmacological findings. It does not provide medical advice, diagnosis, or treatment recommendations. The information on this page reflects flags in our database and should not replace consultation with a qualified healthcare provider. Always discuss supplement-drug combinations with your prescriber or pharmacist.